A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
29/10/2021at 07:20

Few weeks after downgrade: GN Hearing maintains guidance

GN Hearing, which adjusted downward its financial expectations for the year at the beginning of the month, released its Q3 report on Friday morning, maintaining the new guidance.
Photo: GN Store Nord / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

On Friday morning, hearing aid manufacturer GN Hearing presented its third quarterly report of the year. This comes three weeks after the company had to downgrade its 2021 financial guidance, now expecting an organic growth rate of around 16 percent in 2021 compared to the previous 25 percent.

When that happened, GN Hearing also adjusted its EBITA (earnings before interest, taxes, and amortizations) margin guidance to "more than" 12 percent, down from "more than" 16 percent.

In connection with Friday's quarterly report, the hearing aid manufacturer unsurpringsingly reports that it has mantained its new 2021 guidance.

"Unfortunately, we had to revise our financial guidance for the year due to product launch delays. However, we firmly believe that the transformation we have initiated of our R&D setup will secure the new product launches in 2022 that enables our continued journey towards delivering more natural and individualized hearing instruments," CEO at GN Hearing Gitte Aabo says in the press release.

"Further, we are very pleased to finally see the draft over-the-counter regulation, which will open new market opportunities, and we look forward to having the opportunity to comment on FDA's proposal," she adds, referring to the FDA presentation last week of the long-awaited proposal for the regulation of OTC hearing aids.

Organic growth

With the downgrade earlier this month, GN Hearing also unveiled the preliminary third quarter revenue of DKK 1,346m (USD 210m), corresponding to an organic growth of 4 percent compared to the same period last year.

The firm now reports Q3 revenue of DKK 1,347m (USD 211m), and organic growth of 4 percent compared to Q3 of 2020. However, when compared to 2019, before the Covid-19 pandemic, this is still a negative organic growth rate of 6 percent.

For the first nine months of the year, organic growth has been 22 percent – well above the previous expectation for the year's organic growth of 16 percent, which came as a result of the downgrade in beginning of October.

At the end of Q3 2021, the EBITA margin was 12.8 percent, which the same quarter last year also reported. This means that EBITA margin for the first nine months of the year is 10.9 percent against the comparable 2020 period's -3.3 percent.

GN downgrades expectations for GN Hearing significantly

FDA proposes regulation for OTC hearing aids after string of delays 

GN Hearing restructures after research and development letdown 

Related articles:

  • Gitte Aabo, CEO at GN Hearing | Photo: GN Hearing / PR

    GN Hearing restructures after research and development letdown

    For subscribers

  • Photo: GN Store Nord / PR

    GN downgrades expectations for GN Hearing significantly

    For subscribers

  • Photo: Andrew Kelly/REUTERS / X02844

    FDA proposes regulation for OTC hearing aids after string of delays

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Head of International Sales

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Application Manager

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Commercial Director

  • Principal Laboratory Technologist

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

See all jobs

Jobs

  • Head of International Sales

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Application Manager

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Commercial Director

  • Principal Laboratory Technologist

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge